Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Primary Cells Market

ID: MRFR/LS/17960-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026

US Primary Cells Market Research Report: Size, Share, Trend Analysis By Source (Hematopoietic Cells, Skin Cells, Gastrointestinal Cells, Liver Cells, Lung Cells, Skeletal and Muscle Cells), By Types (Human Primary Cells, Animal Primary Cells) and By End Users (Pharmaceutical and Biotechnology Companies, Research Institutes) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Primary Cells Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Pharmaceutical, BY Source (USD Million)
  49.     4.1.1 Hematopoietic Cells
  50.     4.1.2 Skin Cells
  51.     4.1.3 Gastrointestinal Cells
  52.     4.1.4 Liver Cells
  53.     4.1.5 Lung Cells
  54.     4.1.6 Skeletal and Muscle Cells
  55.   4.2 Pharmaceutical, BY Type (USD Million)
  56.     4.2.1 Human Primary Cells
  57.     4.2.2 Animal Primary Cells
  58.   4.3 Pharmaceutical, BY End User (USD Million)
  59.     4.3.1 Pharmaceutical and Biotechnology Companies
  60.     4.3.2 Research Institutes
  61. 5 SECTION V: COMPETITIVE ANALYSIS
  62.   5.1 Competitive Landscape
  63.     5.1.1 Overview
  64.     5.1.2 Competitive Analysis
  65.     5.1.3 Market share Analysis
  66.     5.1.4 Major Growth Strategy in the Pharmaceutical
  67.     5.1.5 Competitive Benchmarking
  68.     5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  69.     5.1.7 Key developments and growth strategies
  70.       5.1.7.1 New Product Launch/Service Deployment
  71.       5.1.7.2 Merger & Acquisitions
  72.       5.1.7.3 Joint Ventures
  73.     5.1.8 Major Players Financial Matrix
  74.       5.1.8.1 Sales and Operating Income
  75.       5.1.8.2 Major Players R&D Expenditure. 2023
  76.   5.2 Company Profiles
  77.     5.2.1 Thermo Fisher Scientific (US)
  78.       5.2.1.1 Financial Overview
  79.       5.2.1.2 Products Offered
  80.       5.2.1.3 Key Developments
  81.       5.2.1.4 SWOT Analysis
  82.       5.2.1.5 Key Strategies
  83.     5.2.2 Merck KGaA (DE)
  84.       5.2.2.1 Financial Overview
  85.       5.2.2.2 Products Offered
  86.       5.2.2.3 Key Developments
  87.       5.2.2.4 SWOT Analysis
  88.       5.2.2.5 Key Strategies
  89.     5.2.3 Lonza Group (CH)
  90.       5.2.3.1 Financial Overview
  91.       5.2.3.2 Products Offered
  92.       5.2.3.3 Key Developments
  93.       5.2.3.4 SWOT Analysis
  94.       5.2.3.5 Key Strategies
  95.     5.2.4 Corning Incorporated (US)
  96.       5.2.4.1 Financial Overview
  97.       5.2.4.2 Products Offered
  98.       5.2.4.3 Key Developments
  99.       5.2.4.4 SWOT Analysis
  100.       5.2.4.5 Key Strategies
  101.     5.2.5 Becton Dickinson and Company (US)
  102.       5.2.5.1 Financial Overview
  103.       5.2.5.2 Products Offered
  104.       5.2.5.3 Key Developments
  105.       5.2.5.4 SWOT Analysis
  106.       5.2.5.5 Key Strategies
  107.     5.2.6 Promega Corporation (US)
  108.       5.2.6.1 Financial Overview
  109.       5.2.6.2 Products Offered
  110.       5.2.6.3 Key Developments
  111.       5.2.6.4 SWOT Analysis
  112.       5.2.6.5 Key Strategies
  113.     5.2.7 F. Hoffmann-La Roche Ltd (CH)
  114.       5.2.7.1 Financial Overview
  115.       5.2.7.2 Products Offered
  116.       5.2.7.3 Key Developments
  117.       5.2.7.4 SWOT Analysis
  118.       5.2.7.5 Key Strategies
  119.     5.2.8 Sigma-Aldrich (US)
  120.       5.2.8.1 Financial Overview
  121.       5.2.8.2 Products Offered
  122.       5.2.8.3 Key Developments
  123.       5.2.8.4 SWOT Analysis
  124.       5.2.8.5 Key Strategies
  125.   5.3 Appendix
  126.     5.3.1 References
  127.     5.3.2 Related Reports
  128. 6 LIST OF FIGURES
  129.   6.1 MARKET SYNOPSIS
  130.   6.2 US MARKET ANALYSIS BY SOURCE
  131.   6.3 US MARKET ANALYSIS BY TYPE
  132.   6.4 US MARKET ANALYSIS BY END USER
  133.   6.5 KEY BUYING CRITERIA OF PHARMACEUTICAL
  134.   6.6 RESEARCH PROCESS OF MRFR
  135.   6.7 DRO ANALYSIS OF PHARMACEUTICAL
  136.   6.8 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
  137.   6.9 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
  138.   6.10 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
  139.   6.11 PHARMACEUTICAL, BY SOURCE, 2024 (% SHARE)
  140.   6.12 PHARMACEUTICAL, BY SOURCE, 2024 TO 2035 (USD Million)
  141.   6.13 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
  142.   6.14 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
  143.   6.15 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
  144.   6.16 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
  145.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  146. 7 LIST OF TABLES
  147.   7.1 LIST OF ASSUMPTIONS
  148.     7.1.1
  149.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  150.     7.2.1 BY SOURCE, 2025-2035 (USD Million)
  151.     7.2.2 BY TYPE, 2025-2035 (USD Million)
  152.     7.2.3 BY END USER, 2025-2035 (USD Million)
  153.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  154.     7.3.1
  155.   7.4 ACQUISITION/PARTNERSHIP
  156.     7.4.1

US Pharmaceutical Market Segmentation

Pharmaceutical By Source (USD Million, 2025-2035)

  • Hematopoietic Cells
  • Skin Cells
  • Gastrointestinal Cells
  • Liver Cells
  • Lung Cells
  • Skeletal and Muscle Cells

Pharmaceutical By Type (USD Million, 2025-2035)

  • Human Primary Cells
  • Animal Primary Cells

Pharmaceutical By End User (USD Million, 2025-2035)

  • Pharmaceutical and Biotechnology Companies
  • Research Institutes

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions